Skip to content

The efficacy and safety of CT20S on the Skin wrinkle improvement

A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the evaluation of the efficacy and safety of CT20S on the Skin wrinkle improvement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004447
Enrollment
120
Registered
2019-11-18
Start date
2019-11-11
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

P&K Skin Research Center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Women over 40 years old and under 55 years old 2) In a visual evaluation, both left and right eye wrinkles are grade 3 or higher 3) Using Corneometer®, measure the amount of water in both cheeks. Left and right cheeks are less than 49AU 4) Those who have agreed to participate in this test prior to the start of the test and have signed a written consent form

Exclusion criteria

Exclusion criteria: 1) Those who have or are currently undergoing treatment for skin diseases such as atopic dermatitis and psoriasis 2) Sensitive or allergic to food ingredients for this human application test 3) People with abnormal skin conditions such as spots, acne, erythema, and capillary dilation in the test area 4) Visit 1 A person who received treatment on the facial (skin stripping, other skin care, etc.) or received treatment on the facial area within 6 months 5) Visitor 1 Use a skin external substance containing steroids on the facial part or take an oral retinoid/steroid agent within 3 months of the standard visit 6) Visitor 1 Use functional cosmetic (retinoid agent, retinol, AHA) or moisturizing cosmetic or skin care (LED mask, ion booster, etc.) to improve wrinkles within 2 weeks of visit 7) People who take diet pills (absorbent and antidepressants, appetite suppressants, etc.) and contraceptives or hormones or diuretics within one month based on visit1 8) Visitors who have taken antioxidants, hyaluronic acid, health function foods containing collagen, moon flower species freedom, vitamin A, vitamin C, vitamin E-containing medicines and health function foods within two weeks of visit1; 9) Visit 1 A person who has participated in other interventional clinical tests (including human application tests) within one month of the standard or plans to participate in other interventional clinical tests (including human application tests) after the start of this human application test. 10) Person whose AST (GOT) or ALT (GPT) is 120IU/L or higher, or whose ?-GTP is 180IU/L or higher 11) Those whose creatine is 2.4 mg/dl or higher 12) A person who is less than or equal to 0.1µIU/ml of TSH or greater than 10µIU/ml of TSH 13) Unregulated hypertension patients (based on measurement after 10 minutes of stabilization, at least 160mmHg of the hydraulic pressure or more than 100mmHg of the relaxant blood pressure) 14) Unregulated diabetics (more than 180 mg/dl per empty blood) 15) People with schizophrenia, depression, drug addiction, etc. 16) Those who are pregnant, nursing, or planning to conceive within three months; 17) Those who are in hospital, drug treatment, and rehabilitation for alcohol use ·Distribution disorder, heart disease, and central nervous disorder 18) Smokers or those who smoke less than a year after quitting smoking 19) A person who judges that the tester is inappropriate for this test

Design outcomes

Primary

MeasureTime frame
skin folds;skin moisture content

Secondary

MeasureTime frame
Transepidermal Water Loss;the thick skin Water Quantity;skin elasticity;Eye wrinkle volume;Evaluation of improvement for testers and human application test takers

Countries

Korea, Republic of

Contacts

Public ContactHae Lee

P&K Skin Research Center

hklee@pnkskin.com+82-2-6925-1501

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026